{"id":842100,"date":"2025-04-25T07:39:09","date_gmt":"2025-04-25T11:39:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/"},"modified":"2025-04-25T07:39:09","modified_gmt":"2025-04-25T11:39:09","slug":"aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/","title":{"rendered":"ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation \u2013 Contact BFA Law if You Lost Money"},"content":{"rendered":"
\n

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP<\/strong><\/a> announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws.<\/p>\n

If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https:\/\/www.bfalaw.com\/cases-investigations\/aldeyra-therapeutics-inc<\/strong><\/a>.<\/p>\n

\n Why is Aldeyra Therapeutics being Investigated? <\/strong>\n <\/p>\n

Aldeyra Therapeutics is a biotechnology company focused on developing therapies designed to treat immune-mediated and metabolic diseases. The company\u2019s lead drug candidate, reproxalap, is being developed for the treatment of dry eye disease.<\/p>\n

During the relevant period, Aldeyra Therapeutics announced the success of its Phase III dry eye chamber clinical trial for reproxalap. The company stated that the trial\u2019s results were \u201cuniquely supportive\u201d of reproxalap\u2019s effect on reducing ocular discomfort and that reproxalap was the first investigational drug with \u201cpivotal data\u201d to support reducing redness. What\u2019s more, the company stated that the trial \u201csatisfies FDA requirements\u201d for New Drug Application resubmission.<\/p>\n

In truth, Aldeyra Therapeutics\u2019 Phase III trial failed to demonstrate reproxalap\u2019s efficacy in treating ocular symptoms associated with dry eyes. The Phase III trial data suffered from potential methodological issues, including a difference in baseline scores across treatment arms, that did not satisfy the FDA requirements for NDA resubmission.<\/p>\n

\n The Stock Declines as the Truth is Revealed<\/strong>\n <\/p>\n

On April 3, 2025, Aldeyra Therapeutics issued a press release stating that the FDA issued a Complete Response Letter for the NDA for reproxalap. The FDA stated that the NDA \u201cfailed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes.\u201d The FDA identified concerns with the trial data submitted with the NDA, which the FDA stated may be related to methodological issues, including a difference in baseline scores across treatment arms. This news caused the price of Aldeyra Therapeutics stock to fall nearly 75% over the course of the trading day, from a closing price of $5.33 per share on April 2, 2025.<\/p>\n

\n Click here for more information: <\/strong>
\n
\n https:\/\/www.bfalaw.com\/cases-investigations\/aldeyra-therapeutics-inc<\/strong>
\n <\/a>
\n .<\/strong>\n <\/p>\n

\n What Can You Do?<\/strong>\n <\/p>\n

If you invested in Aldeyra Therapeutics you may have legal options and are encouraged to submit your information to the firm.<\/p>\n

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.<\/p>\n

\n Submit your information by visiting:<\/strong>\n <\/p>\n

\n
\n https:\/\/www.bfalaw.com\/cases-investigations\/aldeyra-therapeutics-inc<\/strong>
\n <\/a>\n <\/p>\n

Or contact:
Ross Shikowitz
ross@bfalaw.com<\/a>
212-789-3619<\/p>\n

\n Why Bleichmar Fonti & Auld LLP?<\/strong>\n <\/p>\n

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs\u2019 Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.\u2019s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.<\/p>\n

For more information about BFA and its attorneys, please visit https:\/\/www.bfalaw.com<\/a>.<\/p>\n

\n
\n https:\/\/www.bfalaw.com\/cases-investigations\/aldeyra-therapeutics-inc<\/strong>
\n <\/a>\n <\/p>\n

\n Attorney advertising. Past results do not guarantee future outcomes.<\/em>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https:\/\/www.bfalaw.com\/cases-investigations\/aldeyra-therapeutics-inc. Why is Aldeyra Therapeutics being Investigated? Aldeyra Therapeutics is a biotechnology company focused on developing therapies designed to treat immune-mediated and metabolic diseases. The company\u2019s lead drug candidate, reproxalap, is being developed for the treatment of dry eye disease. During the relevant period, Aldeyra Therapeutics announced the success of its Phase III dry eye chamber clinical trial for reproxalap. The company stated that the trial\u2019s results were \u201cuniquely supportive\u201d of … <\/p>\n

Continue reading “ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation \u2013 Contact BFA Law if You Lost Money”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-842100","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation \u2013 Contact BFA Law if You Lost Money - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation \u2013 Contact BFA Law if You Lost Money - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https:\/\/www.bfalaw.com\/cases-investigations\/aldeyra-therapeutics-inc. Why is Aldeyra Therapeutics being Investigated? Aldeyra Therapeutics is a biotechnology company focused on developing therapies designed to treat immune-mediated and metabolic diseases. The company\u2019s lead drug candidate, reproxalap, is being developed for the treatment of dry eye disease. During the relevant period, Aldeyra Therapeutics announced the success of its Phase III dry eye chamber clinical trial for reproxalap. The company stated that the trial\u2019s results were \u201cuniquely supportive\u201d of … Continue reading "ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation \u2013 Contact BFA Law if You Lost Money"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-25T11:39:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyNDk1OSM2ODczODE2IzIyOTA5OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation \u2013 Contact BFA Law if You Lost Money\",\"datePublished\":\"2025-04-25T11:39:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\\\/\"},\"wordCount\":552,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyNDk1OSM2ODczODE2IzIyOTA5OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\\\/\",\"name\":\"ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation \u2013 Contact BFA Law if You Lost Money - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyNDk1OSM2ODczODE2IzIyOTA5OTU=\",\"datePublished\":\"2025-04-25T11:39:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyNDk1OSM2ODczODE2IzIyOTA5OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyNDk1OSM2ODczODE2IzIyOTA5OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation \u2013 Contact BFA Law if You Lost Money\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation \u2013 Contact BFA Law if You Lost Money - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/","og_locale":"en_US","og_type":"article","og_title":"ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation \u2013 Contact BFA Law if You Lost Money - Market Newsdesk","og_description":"NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https:\/\/www.bfalaw.com\/cases-investigations\/aldeyra-therapeutics-inc. Why is Aldeyra Therapeutics being Investigated? Aldeyra Therapeutics is a biotechnology company focused on developing therapies designed to treat immune-mediated and metabolic diseases. The company\u2019s lead drug candidate, reproxalap, is being developed for the treatment of dry eye disease. During the relevant period, Aldeyra Therapeutics announced the success of its Phase III dry eye chamber clinical trial for reproxalap. The company stated that the trial\u2019s results were \u201cuniquely supportive\u201d of … Continue reading \"ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation \u2013 Contact BFA Law if You Lost Money\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-25T11:39:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyNDk1OSM2ODczODE2IzIyOTA5OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation \u2013 Contact BFA Law if You Lost Money","datePublished":"2025-04-25T11:39:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/"},"wordCount":552,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyNDk1OSM2ODczODE2IzIyOTA5OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/","name":"ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation \u2013 Contact BFA Law if You Lost Money - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyNDk1OSM2ODczODE2IzIyOTA5OTU=","datePublished":"2025-04-25T11:39:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyNDk1OSM2ODczODE2IzIyOTA5OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyNDk1OSM2ODczODE2IzIyOTA5OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aldx-shareholders-aldeyra-therapeutics-inc-nasdaqaldx-75-stock-drop-triggers-investigation-contact-bfa-law-if-you-lost-money\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation \u2013 Contact BFA Law if You Lost Money"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/842100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=842100"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/842100\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=842100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=842100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=842100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}